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Abstract
Background: To examine the expression of type 1 plasminogen inhibitor (PAI-1) in clear cell renal cell carcinoma
(CCRCC), and its possible association with microvessel density (MVD), the expression of thrombospondin-1 (TSP-1),
nuclear grade, tumour stage, continuously coded tumour size (CCTS) and to assess the value of PAI as a prognostic
marker in 162 patients with CCRCC treated with radical nephrectomy.
Methods: A total of 172 consecutive patients with CCRCC treated with radical nephrectomy were enrolled in the
study. The expression of PAI-1, TSP-1 and factor VIII were analysed on formalin-fixed, paraffin-embedded tissues
without knowledge of the clinical outcome. Ten cases, where PAI-1 immunohistochemistry was not possible due
to technical problems and lack of material, were excluded. Sixty-nine patients (43%) died of RCC, while 47 patients
(29%) died of other diseases. Median follow-up was 13.8 years for the surviving 46 patients (28%).
Results: Nine percent of the tumours showed PAI-1 positivity. High expression of PAI-1 was significantly inversely
correlated with TSP-1 (p = 0.046) and directly with advanced stage (p = 0.008), high NG (3+4) (p = 0.002), tumour
size (p = 0.011), microvessel density (p = 0.049) and disease progression (p = 0.002). In univariate analysis PAI-1 was
a significant prognosticator of cancer-specific survival (CSS) (p < 0.001). Multivariate analysis revealed that TNM
stage (p < 0.001), PAI-1 (p = 0.020), TSP-1 (p < 0.001) and MVD (p = 0.007) were independent predictors of CSS.
Conclusions: PAI-1 was found to be an independently significant prognosticator of CSS and a promoter of tumour
angiogenesis, aggressiveness and progression in CCRCC.
Background
Angiogenesis is considered essential for tumour growth
and metastasis. Increased angiogenesis in different
tumours, as measured by microvessel density, is a pre-
dictor of adverse prognosis [1]. Its regulation is complex
and the balance between pro- and antiangiogenic factors
in a given tissue microenvironment, determines the
angiogenic phenotype.
Type 1 plasminogen inhibitor (PAI-1) is a serine protease
catalysing the conversion of plasminogen to plasmin, and is
considered an important measure of tumour vascular
remodelling and neovascularisation as described in breast
carcinoma [2]. Despite this contention, melanoma growth
has been found to be unaffected by the levels of PAI-1
expression [3]. PAI-1 has also been found to be a potent
inhibitor of cell migration and angiogenesis and therefore
was thought to inhibit invasion and metastasis [4]. Further-
more, it has been suggested that PAI-1 can either enhance
or inhibit tumour growth and angiogenesis depending on
its concentration [5]. In several carcinomas PAI-1 expres-
sion has been found to be higher than in normal cells and
associated with tumour growth, invasion, and metastasis
[6,7]. Divergent results have also been reported about the
clinical significance of the urokinase-type plasminogen acti-
vator (u-PA) system in renal cell carcinoma (RCC)
[5,6,8-10]. Thus, the biological role of PAI-1 is complex
and its clinical importance remains controversial.
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CCRCC is known to be a highly vascularised tumour.
We therefore hypothesized that the expression of PAI-1
might have an important role for the biological beha-
viour of this type of tumour and thus may prove to be
of future importance for treatment.
The purpose of this study was to evaluate the occur-
rence and expression pattern of PAI-1 in CCRCC by
using immunohistochemistry; to assess a possible asso-
ciation between the PAI-1 expression pattern and
microvessel density (MVD), the expression of TSP-1,
nuclear grade (NG), tumour stage and size; and finally
to examine the impact of PAI-1 on tumour progression
and cancer-specific survival (CSS) in CCRCC.
Methods
Patients
The patient material in this series is described in detail
elsewhere [11]. Briefly, a total of 172 consecutive
patients with CCRCC treated with radical nephrectomy
(RN) during the years 1985 - 1994 were enrolled in the
study. However, due to technical problems and lack of
material, 10 cases where PAI-1 immunohistochemistry
could not be performed, were excluded from the study.
The specimens were examined at the Department of
Pathology, Central Hospital, Karlstad, and the Depart-
ment of Pathology, Haukeland University Hospital,
Bergen. Tumour staging was ranked according to the
2002 TNM classification system using the American
Joint Committee on Cancer (AJCC) stage grouping [12].
The nuclear grading was ranked according to Fuhrman
[13] and dichotomized into a two-grade system: low-
grade (Fuhrman NG 1 and 2) and high-grade (Fuhrman
NG 3 and 4). Continuously coded tumour size (CCTS)
was given in cm by measuring the greatest diameter.
Approval to use the biological material for research
purposes was granted in 2004 by the local authority at
Karlstad Central Hospital in Sweden according to Swed-
ish regulations. In Norway the appropriate Norwegian
authority, Norwegian Social Science Data Services,
recognized this approval. The study was carried out in
accordance with the standards of World Medical Asso-
ciation Declaration of Helsinki as revised in 2008.
Follow-up
Complete information on the cause of death was avail-
able in all 162 cases. Last date of follow up was April
30th, 2004, and median follow up for the population stu-
died was 5.6 years; mean 7.0 years (range 0.01-19.4
years). The median follow-up for the surviving 46
patients (28%) was 13.8 years.
Immunohistochemistry (IHC)
Immunohistochemistry was performed on 4 μm sec-
tions from formalin-fixed, paraffin-embedded tissues.
The slides were deparaffinised microwaved for 15 min-
utes and incubated in 60 minutes with the primary
antibody: the TJA6 clone, Novocastra Laboratories Ltd.
The staining procedures were performed on DAKO
Tech-Mate 500 slide processing equipment. Antigen
localisation was revealed by the standard avidin-biotin-
peroxidase method. Harris haematoxylin was used for
counterstaining. Positive and negative controls were
used. Necrotic areas, prominent hyalinization, and
hemorrhagic areas were excluded from the analysis.
The staining procedures, analyses and antibodies used
concerning MVD and TSP-1 expression have been
described previously[14].
As shown in Figure 1(a, b, c, d), cytoplasmic PAI-1
reactivity was detected in RCC cells. Staining of stromal
cells was not found.
Semiquantitative analysis of PAI-1 and data processing
Screening for intratumoral hot spots under low power
magnification (100× magn., Olympus BX51 microscope)
revealed the areas with the highest staining intensity for
PAI-1.
Ten representative images at ×400 magnification in
the hot spot areas were taken by photomicroscope
(Olympus U-Tvo.5×c). The expression level was quanti-
fied by computing the percentage of representatively
stained surface-area in the image. The mean value for
each phase fraction (intensity level) in the ten images
(HPF; ×400) was calculated. The highest value deter-
mined the staining intensity level of the tumour.
Tumour sections were classified as having low PAI-1
expression when they showed no or negligible/equivocal
reactivity (score 0-1). Tumours with detectable PAI-1
Figure 1 PAI-1 antigen expression in CCRCC. a) cytoplasmic PAI-
1 staining in areas with high NG; b) weak staining in areas with low
NG c) single scattered highly atypical PAI-1 positive tumour cells
(arrows); d) strong expression in areas with sarcomatoid
dedifferentiation.
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immunoreactivity were considered to have moderate or
high PAI-1 expression (score 2-3) (Figure 1a-d).
All analyses were accomplished in the AnalySIS Image
Processing [Microsoft Windows NT5.0 (Build 21915)
Service Pack 4]. For a better understanding of the rela-
tionship between growth and progression of CCRCC tis-
sues that contain PAI-1 proteins, we also looked for a
possible correlation to MVD (Factor VIII) and TSP-1.
The Semiquantitative analysis of MVD and TSP-1 are
reported elsewhere [14].
Statistical procedures
The association between categorical baseline variables
was characterized by cross tabulations and tested using
exact chi-square tests for associations between dichoto-
mized variables, and using exact Mann-Whitney tests
for associations between dichotomized and ordinal or
continuous variables. The associations between time to
progression and baseline characteristics were investi-
gated by univariate Cox regression. Microvessel density
was dichotomized at the mean value for all 162 patients
CSS, and was investigated by univariate and multivariate
Cox regression. Univariate relationships were also inves-
tigated by Kaplan-Meyer analysis.
For multivariate Cox regression for CSS by PAI-1 sta-
tus, adjustments were made for stage, TSP-1, nuclear
grade, MVD and CCTS. Harrell’s concordance index
[15] was used to characterise predictive accuracy. Statis-
tical significance was defined as p < 0.05. SPSS Statistics
17.0 (SPSS Inc, Chicago, IL, USA) and R (the R Founda-
tion for Statistical Computing, Vienna, Austria) were
used for the analyses.
Results
According to the 2002 TNM AJCC classification, 48
tumours (30%) were pT1 stage, 24 (15%) pT2, 46 (28%)
pT3, and 44 (27%) stage pT4. One hundred- and nine-
teen tumours (74%) were of low grade (NG1 and -2)
and 43 tumours (26%) were high grade (NG3 and -4).
Fourteen tumours (9%) showed cytoplasmic PAI-1 posi-
tivity. One of the PAI-1 positive tumours was stage I,
two were stage II, two stage III and nine were stage IV
tumours. The intensity levels and expression patterns
were heterogeneous and strongest in the cells of high
NG (Figure 1a). Areas of low NG were either negative
or rather weak staining of PAI-1 was found (Figure 1b).
In some tumours only single scattered severely atypical
cells showed intense cytoplasmic positivity (Figure 1c).
The strongest expression was found in areas with sarco-
matoid dedifferentiation (Figure 1d). Ten (71%) of the
PAI-1-positive tumours exhibited high MVD compared
to 59 (42%) of the PAI-1 negative tumours (p = 0.049).
The presence of PAI-1 was inversely associated with
TSP-1 expression (p = 0.046). Twelve PAI-1 positive
tumours (86%) were found to have low or no TSP-1
staining, compared to 82 (57%) of the PAI-1 negative
tumours. PAI-1 expression correlated with tumour stage
(p = 0.008). Nine tumours with PAI-1 positivity (64%)
were classified as TNM stage IV compared to 35 (24%)
of the PAI-1negative tumours.
The median diameter of PAI-1-negative tumours was
7.0 cm and of PAI-1-positive tumours 9.0 cm (p =
0.014). PAI-1 expression correlated positively with NG
(p = 0.002). Nine (64%) of the 14 PAI-1 positive
tumours had high NG (3+4), compared to 34 (23%) of
the 148 tumours with low or no PAI-1 expression.
In univariate Cox regression- and Kaplan-Meier analy-
sis depicted in Figure 2, PAI-1 expression was a signifi-
cant prognostic factor for CSS (p < 0.001) with HR of
6.49 (95% CI 3.32 - 12.68). Analyses of CSS of stage,
NG, MVD and TSP-1 are reported elsewhere [14]. The
multivariate analysis showed that PAI-1 expression (p =
0.02, HR = 2.32), TSP-1, stage, and MVD were indepen-
dently significant predictive factors for CCS (Table 1).
However, NG and CCTS were not found to be indepen-
dent predictors of CSS (p = 0.341) and (p = 0.837)
respectively (Table 1). Harrell’s concordance index was
0.847 (0.831 after optimism correction).
An extremely high HR for development of metachro-
nous distant metastases in patients with PAI-1 positive
tumours was found (HR = 13.71, 95% CI 2.57 - 73.14)
(p = 0.002).
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Figure 2 PAI-1 expression and cancer-specific survival in 162
patients with CCRCC undergoing radical nephrectomy.
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Discussion
The present population-based study represents one of the
largest series to date that investigates the occurrence and
role of PAI-1 in CCRCC. The PAI-1 expression was
found to be significantly associated with nuclear grade
tumour stage and support the findings of Ohba et al. [8]
but contradict the conclusions of Chautard et al. [10].
The fact that the results in different studies of RCC are
somewhat diverging, may be explained by differences in
the populations studied and tumour sampling. It has to
be emphasized that, different methodology (cytosolic
assay vs. immunohistochemical methods), has been used
in these studies. Furthermore, heterogeneous distribution
of PAI-1 in RCC was revealed in our study, which indi-
cates the importance of tumour sampling. Finally, the fol-
low-up time in our study was substantially longer.
Our findings indicate that PAI-1 positivity correlates
with high MVD, and tumour growth. These findings
support previous reports suggesting a possible promot-
ing function of PAI-1 in tumour growth by its potential
to modify cell adhesion [7]. The absence of host PAI-1
has been shown to prevent tumour invasion and its pre-
sence to be essential for regulation of tumour cell inva-
sion and metastasis by promoting angiogenesis [5].
We found that the risk of progression of non-meta-
static PAI-1-positive tumours was extremely high (HR =
13.71) (p = 0.002). This is in accordance with a recent
study showing the overexpression of PAI-1 to be signifi-
cantly associated with the presence of bone metastasis
in CCRCC [16]. It has been demonstrated that PAI-1
mRNA and protein levels were dramatically increased in
RCC cells expressing mutant or lacking von Hippel-
Lindau (VHL) tumour-suppressor genes compared with
cells expressing wild type VHL [17]. Moreover, PAI-1
has also been shown to be regulated by hypoxia induci-
ble factor (HIF2a) [18]. In line with the findings of pre-
vious studies on various carcinomas [2] we found that
high expression of PAI-1 was associated with high
tumour stage and significantly lower survival rate.
PAI-1 expression occurs in CCRCC and it was found
to be an independent predictor of cancer-specific survi-
val. The expression is cytoplasmic and heterogeneously
distributed and seems to be strongest in high grade
tumours. PAI-1 positivity is significantly correlated with
MVD, NG, tumour stage, size and progression and
inversely with TSP-1. Our results show that PAI-1 inde-
pendently influenced CSS of patients with CCRCC con-
firming the results of previous comparable studies [8,9].
The high correlation between PAI-1 expression and tra-
ditional clinical and pathological prognostic parameters
like tumor stage, tumor size, nuclear grade and sarcoma-
toid differentiation may limit the added prognostic utility
of this marker in RCC. However, our findings give strong
support to the conclusion that PAI-1 may turn out to be a
valuable molecular and biochemical marker for tumour
aggressiveness, which can be used as a supplement or pos-
sible substitute to standard morphological methods.
Most of the tumours with PAI-1 expression were stage
T3/T4. Two of the 3 patients having PAI-1 positive
stage T1/T2 tumours died in RCC. Even though there
were very few PAI-1 positive tumours in organ confined
stages (T1/T2), this molecular marker turned out to be
a highly significant predictor of developing metachro-
nous metastasis in these patients with HR = 13,71 (p =
0.002). Further studies, however, seems necessary to
fully reveal the prognostic impact of PAI-1 expression in
T1-T2 tumours.
Conclusions
We conclude that PAI-1 may have a significant role in
angiogenesis, tumour growth and progression in
CCRCC and may be used as a valuable molecular mar-
ker in prognostic nomograms for CCRCC. Our study
indicates that illuminating the biological role of PAI-1
in CCRCC may lead to the development of new thera-
peutic modalities to control angiogenesis and tumour
progression.
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Table 1 Cancer specific survival (CSS) and
clinicopathological findings in 162 patients operated
with radical nephrectomy for clear cell renal cell
carcinoma; multivariate analysis
Cancer specific survival (CSS)
HR 95% CI p-value
PAI-1 expression
No or low (ref.)
Medium/High 2.92 1.15 - 4.87 0.020
TNM stage group < 0.001
I ref.
II 2.52 0.75 - 7.56 8.74
III 2.99 1.11 - 7.56 0.030
IV 11.60 4.27 - 31.44 < 0.001
Microvessel Density
Low (ref.)
High 2.19 1.24 - 3.85 0.007
TSP-1
High (ref.)
Low 3.69 1.74 - 7.81 0.001
Nuclear grade
(1+2) (ref.)
(3+4) 1.29 0.76 - 2.18 0.341
Continuously coded
Tumour size 1.01 0.92 - 1.11 0.837
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